Post Market Clinical Study of an Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders: * Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris
• Adult men or women
• Excessive Hairiness:
• Patient with unwanted hair on the body (legs, arms, bikini line, or axilla)
• Patient over 18 years.
• Patients with Fitzpatrick skin types from I to V.
• Women were required to be post-menopausal, surgically sterilized, or under a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, or barrier methods with spermicide or abstinence) during the study time period.
⁃ Vascular lesions:
• Patients over 18 years.
• Patients with Fitzpatrick skin types from I to IV.
• Patients with varicosities and Rosacea on the face or upper and lower limbs.
⁃ Pigmented lesions:
• Patients over 18 years.
• Patients with solar lentigines on their cheeks, back, hands, arm and leg (\> 3 mm).
• Patient with Fitzpatrick skin type from I to IV.
⁃ Acne:
• Patients over 18 years
• Patients with Fitzpatrick skin types from I to IV.
• Patients with facial acne vulgaris on face.
• Willing to sun protect treated area for the duration of enrollment in the study and 4 weeks after treatment.